[106]
This being said, Prothonotary Milczynski's decision makes it clear that the reason why she is of the view that, "with limited exceptions, Novopharm has failed to discharge its onus" is because Novopharm has not provided sufficient evidence to satisfy the
Sierra Club
test and other related jurisprudence. Assertions are made, but mere assertions are not enough:
"There is no evidence substantiating these assertions, only speculation."